Note: Descriptions are shown in the official language in which they were submitted.
2097~
SLOW-RELEASE SODIUM VALPROATE TABLETS
.. s~
' '
` FIELD OF THE INVENTION
This invention relates to slow-release sodium valproate
tablets.
BACKGROUND OF THE INVENTION
Sodium valproate (2-propylpentanoic acid sodium salt)
is a useful drug widely employed for treatment of epilepsy and
prevention of ictus epilepticus. The effective blood
concentration of the drug generally ranges from 50 to
100 ~g/mQ. Because sodium valproate has a short biological
half-life, sodium valproate must be administered three times a
day to maintain an effective blood concentxation. Since such
a short dose interval is troublesome for patients, there have
been many efforts to develop long-acting, slow-release
preparations of sodium valproate.
However, sodium valproate should be administered at a
relatively high daily dose approaching 1200 mg. Moreover,
sodium valproate is highly hygroscopic. Hence, conventional
slow-release tablets comprise a relatively large proportion of
adjuvants, such as retarders, and therefore are
unsatisfactorily weighty and bulky.
Recently proposed techniques for preparing slow-release
tablets of sodium valproate include (a) a process comprising
preparing granules from a mixture of sodium valproate and
magnesium aluminometasilicate using ethyl cellulose as a binder
, ~ . . .
,
.~ . .
209716~
and tabletlng the same (see JP-A-62-81309, the term "JP-A" as
used herein means an unexamined published Japanese patent
application~) and (b) a process comprising mixing valproic
acid, having ethyl cellulose dissolved therein, with a mixture
of Eudragit (an acrylic polymer) manufactured by Rohm Pharma
and sodium valproate, followed by granulation and tableting of
the same (see U.S. Patent 5,017,613 corresponding to JP-A-60-
41610).
The slow-release tablets obtained by process (a) do not
maintain the optimal blood concentration, with the
concentration decreasing considerably after 10 hours of
administration. The slow-release tablets obtained by process
(b) are pH sensitive. Hence, the rate of drug dissolution
varies with the pH in the various portions of the digestive
tract and thus the blood concentration is susceptible to wide
variation.
SUMNARY OF THE INVENTION
An object of the instant invention is to provide slow-
release sodium valproate tablets which are relatively compact,
easy to ingest and can be administered once a day.
Another object of the instant invention is to provide
slow-release sodium valproate tablets which dissolves at a
stable rate irrespective of pH conditions.
As a result of extensive investigation, the instant
inventors have found that sodium valproate preparations
obtained by coating sodium valproate cores with ethyl
. . ~ . .
- - ' ' . ' ' - ~ - .
.' ~
209~164
cellulose, having uniformly dispersed therein silicic acid
anhydride, ~ile having a relatively small size, have a
constant rate of dissolution under varying pH conditions and
exhib.it stable and satisfactory slow release properties. The
instant invention has been completed based on that finding.
The instant invention relates to a slow-release sodium
valproate tablet with a coating layer, obtained by coating a
core containing sodium valproate with a coating agent
comprising ethyl cellulose having dispersed therein silicic
acid anhydride.
BRIEF DESCRIPTION OF_THE DRAWIN&S
Fig. 1 is a graph of dissolution rate of sodium
valproate over time of slow-release tablets of the present
invention (Tablet A). A solid line and a dotted line stand for
distilled water and J. P. first solution, respectively.
Figs. 2 to 4 each is a graph of dissolution rate of
sodium valproate over time of comparative tablets (Tablets B,
C and D). A solid line and a dotted line stand for distilled
water and J. P. first solution, respectively.
Fig. S is a graph of blood concentration in human
(p.o.) over time of slow-release tablets of the instant
invention.
DETAILED_DESCRIPTION OF THE INVENTION
Cores of the sodium valproate tablets which can be used
in the instant invention axe not limited particularly, and any
~odium valproate tablets prepared by conventional techniques
-- 3 --
2Q97164
can be used as they are. Such tablets are prepared by, for
example, unifQrmly mixing sodium valproate with adjuvants, such
as vehicles and binders, granulating the mixture in a usual
manner, adding appropriate lubricants thereto, followed by
punching.
- Adjuvants, which are used for improvement of molding
properties, regulation of granule size and protection against
moisture, include vehicles, such as silicic acid anhydride,
higher fatty acid metal salts (e.g., calcium or magnesium salt
of stearic acid, palmitic acid or myristic acid); binders, such
as hydroxypropyl cellulose, polyethylene glycol and
polyvinylpyrrolidone; and lubricants, such as calcium stearate,
magnesium stearate, white carbon and silicic acid anhydride.
The slow-release sodium valproate tablets of the
instant invention are prepared by coating cores containing
sodium valproate with an ethyl cellulose solution, having
silicic acid anhydride uniformly dispersed therein, by spray
coating in a usual manner.
Silicic acid anhydride which can be used in the coating
agent is selected from those species which are insoluble in
water and dispersible in w~ter or organic solvents to form
colloidal suspensions.
Coating agents are prepared by dissolving ethyl
cellulose in a lower alcohol, e.g., methyl alcohol or ethyl
alcohol, at a concentration of ~rom about 2 to 10% by weight,
preferably from 4 to 6% by weight, and dispersing therein from
2Q9716~
0.1 to 0.7 parts by weight, and preferably from 0.2 to
0.5 parts by weight, per part by weight of ethyl cellulose, of
silicic acid anhydride. The coating agent usually is applied
to the core in an amount of from about 2 to 10~ by weight, and
preferably from about 3 to 8% by weight, based on the weight of
the core. - .
The rate of dissolution of sodium valproate from the
slow-release tablets thus obtained may be controlled by varying
the mixing ratio of silicic acid anhydride in t.he coating agent
or the amount of the coating agent applied. The higher the
silicic acid anhydride ratio or the lower the amount of the
coating agent, the faster the overall dissolution of the
tablets. Conversely, the lower the silicic acid anhydride
ratio or the higher the amount of the coating agent, the slower
the overall dissolution of the tablets, meaning slower release
of the active agent.
Further, at a higher silicic acid anhydride mixing
ratio, the dissolution rate is less dependent on the amount of
coating agent and it is possible to obtain stable tablets.
However, at too high a silicic acid anhydride mixing ratio, the
tablets may not exhibit slow release properties. For those
reasons, the silicic acid anhydride mixing ratio preferably is
selected from the above range.
The technLque of the instant invention also can be
applied to preparations of other similar drugs having high
water solubility.
_ 5 _
2~971~l~
The instant invention now will be illustrated in
greater detail by way of Examples, Comparative Examples and
Test Examples, but it should be understood that the instant
invention is not to be construed as being limited thereby. All
the percents are given by weight unless otherwise indicated.
EXAMPLE 1
(a) Preparation of Cores:
Sodium valproate weighing 1600 g and 160 g of silicic
acid anhydride, ~Aerosil-200~ (a product of Nippon Aerosil Co.,
Ltd.), were mixed thoroughly, and the mixture was kneaded with
608 g of an ethanol solution containing 5% hydroxypropyl
cellulose. The blend was dried in a hot air drier at 60C and
passed through a 16-mesh sieve. The resulting granules were
mixed with 1% calcium stearate and compression molded to obtain
core tablets each weighing 228.6 mg and having a diameter of
8.5 mm.
(b) Preparation of Slow-release Tablets:
A thousand core tablets obtained in (a) above were
fluidized in a fluidized bed coating apparatus, "Uniglatn
(manufactured by Okawara Seisakusho Co.) and spray-coated with
a coating agent comprising a 5% ethanol solution of ethyl
cellulose (ethoxy content: 46 to 51%) having dispersed therein
1% Aerosil-200 to obtain slow-release sodium valproate tablets
each weighing 236.3 mg ~the coating layer weight: 7.7 mg). The
resulting coated tablets were designated tablets A.
-- 6 --
.
.
.
2097~64
EXAMPLE 2
~ low-releàse sodium valproate tablets (designated
tablets E, F or G) were prepared in the same manner as in
Example 1, except that 1000 core tablets each weighing 226.7 mg
and having a diameter of 8.5 mm were fluidized in a fluidized
bed coating apparatus, I'Uniglat'' (manufactured by Okawara
Seisakusho Co.) and spray-coated with a coating agent
comprising a 5% ethanol solution of ethyl cellulose (ethoxy
content: 46 to 51~) having dispersed therein Aerosil-200 in an
amount varying from 1 to 1.5%. The particulars of the
resulting coated tablets are shown below.
Tablets E Tabléts P Tablets G
Aerosil-200 1% 1.25% 1.5%
Tablet Neight234.5 mg 237.5 mg 243.3 mg
Coating Layer Weight 7.8 mg 10.8 mg 16.6 mg
EXAMPLE 3
Sodium valproate weighing 400 g and 80 g of Aerosil-200
were mixed thoroughly, and the mixture was kneaded with 216 g
of an ethanol solution containing 5% hydroxypropyl cellulose.
The blend was dried in a hot air drier at 60C and passed
through a 16-mesh sieve. The resulting granules were mixed
with 1% calcium stearate and compression molded to obtain core
tablets each weighing 246.2 mg and having a diameter of 8.5 mm.
A thousand core tablets thus obtained were spray-coated
with a coating agent comprising a 5% ethanol solution of ethyl
,, .
2097~B~
cellulose (ethoxy content: 46 to 51%) having dispersed therein
1.25% Aerosil-200 in the same manner as ir. Example 2 to obtain
slow-release sodium valproate tablets (designated tablets H)
each weighing 256.4 mg (the coating layer weight: 10.2 mg).
EXAMPLE 4
.
Sodium valproate weighing 400 g, 40 g of Aerosil-200 and
lO g of a carboxyvinyl polymer were mixed thoroughly and
kneaded with 140 g of a 5% ethanol solution of hydroxypropyl
cellulose. The blend was dried in a hot air drier at 60C and
passed through a 16-mesh sieve. The granules were mixed with
1% magnesium stearate and then punched out to obtain core
tablets each weighing 231.2 mg and having a diameter of 8.5 mm.
A thousand core tablets were spray-coated with a coating
agent comprising a 5% ethanol solution of ethyl cellulose
(ethoxy content: 46 to 51%) having dispersed therein 1%
Aerosil-200 in the same manner as in Example 2 to obtain slow-
release sodium valproate tablets (designated tablets I) each
weighing 239.9 mg (coating layer weight: 8.7 mg).
EXAMPLE 5
Sodium valproate weighing 600 g and 120 g of Aerosil-~00
were mixed thoroughly and kneaded with 348 g of a 5% ethanol
solution of hydroxypropyl cellulose. The blend was dried in a
hot air drier at 60C and passed through a 16-mesh sieve. The
granules were mixed with 1% magnesium stearate and then
compression molded to obtain core tablets each weighing
454.6 mg and having a diameter of 10.5 mm.
. ~
-- 8 --
: ' ~
: ~ -- . . ,
2097~ 6~
A thousand core tablets were spray-coated with a coating
agent compris.ing a 5% ethanol solution of ethyl cellulose
(ethoxy content: 46 to 51~) having dispersed therein 1.25%
Aerosil-200 in the same manner as in Example 2 to obtain slow-
release sodium valproate tablets (designated tablets J) each
weighing 472.9 mg (coating layer weight: 18.3 mg).
EXAMPLE 6
Three thousand core tablets each weighing 226.8 mg and
having a diameter of 8.5 mm which were prepared in the same
manner as in Example 1-(a) were spray-coated with a coating
agent comprising a 5% ethanol solution of ethyl cellulose
(ethoxy content: 46 to 51%) having dispersed therein 2.5%
Aerosil-200 while being rotated by means of an automatic film
coating apparatus, ~FM 2SIl (manufactured by Freund Industrial
Co., Ltd.) to obtain slow-release sodium valproate tablets
(designated tablets K) each weighing 240.1 mg (coating layer
weight: 13.3 mg).
SOMPARATIVE EXAMPLES 1 TO 3
A thousand core tablets obtained in Example l-(a) were
spray-coated in the same manner as in Example l-(b), except for
using, as a coating agent, a 5% ethanol solution of ethyl
cellulose (ethoxy content: 46 to 51%) (Comparative Example 1),
a 5% ethanol solution of ethyl cellulose (ethoxy content: 46 to
51%) having dispersed therein 1% calcium stearate (Comparative
Example 2), or a 5% ethanol solution of ethyl cellulose (ethoxy
content: 46 to 51%) having dispersed therein 1~ fatty acid
_ g _
., .
.
209716~
monoglyceride, ~Myvacet~ (produced by Eastman Kodak Co.), to
prepare tablçts B each weighing 233.1 mg (coating layer weight~
4.5 mg), tablets C each weighing 233.0 mg (coating layer
weight: 4.4 mg) and tablets D each weighing 234.5 mg (coating
layer weight: 5.9 mg), respectively.
TEST EXAMP~E 1
Dissolution Test
Tablets A prepared in Example 1 and tablets B, C and D
prepared in Comparative Examples 1 to 3 were tested according
to the second method of dissolution test (paddle method)
specified in Pharmacopoea Japonica, 12th Ed. (hereinafter
referred to J. P.) (number of rotation: 100 rpm) using as a
testing solution, 900 mQ of water (distilled water) or a first
solution (pH=1.2) specified in the J.P~ disintegration test.
Samples were obtained at various time points, and the
amount of dissoluted sodium valproate was measured by HPLC.
The results obtained are shown in Table 1 and in Figs. 1 to 4.
_ 10 --
.
;~09~164
r ~
c~ ~
¦ r ~ o r-l
r- ¦ ~ co a~ ,
¦ O N 01 t~ ~ Ul 0~ ~
N
r ol
l Ct~
¦U _l ~D ~ U') ,
O ¦ N t~
l ~
~1 l ~i_~ N O 1~1~ U~
IY l ~D ~ Il') O
~ l d' d'
J~ co ~ cn a~ ~ ~ ~ ~1 ,,
~~ NO ~ N ~
O ~
r ¦ t~
U~
c~
a~ ~ ~ O ~ O
~ ~, ,~ $ ~ $ 4
E~ C ~ ~ ~ ~ ~a 1, u
:: : :
a ~ m c~ a
I
: - - .
209716~
. The results of the dissolution test reveal that the sodium
va-lproate tablets A according to the instant invention show
pract.ically the same dissoluting behavior in both water and the
J.P. first solution (pH=1.2) over a long period of time,
thereby establishing the pH-independent nature of the slow-
release tablets of the instant invention. To the contrary,..
tablets B using ethyl cellulose only as a coating agent,
tablets C using ethyl cellulose in combination with calcium
stearate as a coating agent and tablets D using ethyl cellulose
in combination with a fatty acid monoglyceride as a coating
agent exhibit faster dissolution in the J.P. first solution
than in water, indicating that the coating agents used in
tablets B, C and D fail to furnish pH-independent slow-release
tablets.
TEST EXAMPLE 2 :
Dissolution Test
A dissolution test was conducted on tablets E to K prepared
in Examples 2 to 6 in the same manner as in Test Example 1.
Thé results obtained are shown in Table 2 below.
. .
.
-,
: . . .
2097164
~ ~ U~ ~ o~ ~ o~ ~ ~o ~ CO ~
CC~ ~ Il') cr~ ~ r-l d' C~ O ~ r~l O 1~
~ a~ 0 ~ o~ 01
' I `' cr~ o
r ll¦ O d'
--~¦ ~ ~D ~ ~ C~ ~ ~ ~ ~ 1-- 0
. I I
~ ~r O 11'i ~
_ C _l er d'
I U ~ O
L ao ~ ~ o o u~ ~ ~
I C u~
~ I
_ _ ~ ~o a~ er ~ CO In ~ ~ ~ ~ ~ G~ I` ,
t'~l I ~ Isi 0~ ui O --I r l ~D 0 0 a~ ~ ~ ~r O
I U
~c . .'.
l d~ `I O 11~
J~ ~r o ~ ~ ~ o ~ o co
P~ ~ ~
I
u~ u~ ~ o r l ~ ~
I ~ I I r; t~ ~ ~ ~r ~ ~ ~ r l ~ o o
I I I r1 I I / r l ~ r ~ r l ~ ~
.,
a
~ O 3~ u C~ 3 $-1 g ~ 1~ 8 3 ~ .0
3 ~
u r~ o --I O --I O ~1 0 r~ u~
r¦ r¦ r¦ r~
~I
~1~ C H 1~ t4
0
- 13-
.
- ::
:
' ': . ~ :
209716~
TEST EXAMPLE 3
-- in vivo Test (p.o.~
Four tablets of the slow-release sodium valproate tablets
A prepared in Example 1 (total content of sodium valproate:
about 800 mg) were given orally to each of 6 healthy male
adults ranging in age from 22 to 29 (average age: 24.2 years)
and in body weight from 56 to ~8 kg (average b.w.: 64.4 kg).
Changes of sodium valproate concentration in blood were
observed over time. The subjec~s fasted for 12 hours before
the test and for 4.5 hours after administration of the tablets
and prohibited from taking alcohol during the testing period.
Blood samples were taken immediately before administration
and after 1, 2, 4, 6, 8, 10, 12, 24, 30 and 48 hours from
administration. The serum was separated from the blood sample
and sodium valproate content in the serum was measured by gas
chromatography. The results obtained are shown in Table 3 and
in Fig. 5.
- 14 -
: , .
: .
: .
209716~
t~ o
CO ~ ~ ~ ~ U~
o ~ o
~ a~ o o~ ~ ~ ~ o~
o
t~
O ~ d' _~
~r
r-l N O ~ 0`1 ~n 1`
O ~ _~ OD O
_ _I o c~
_ ~ r~
~c
~ o
O O O ~ ~ N ~ ~
.~ ~1 ~ cn o 1` ~ ~ ~ In
:
u~ r~ co ~ t- co
,1 t~
. r~ ~ ~
~:
h ~Dl . . . . . . ~ .
o ~ o 1`
d' ~ ~ ~ ~
~ ~1
E~ ~r u
O O~ O ~ u~
_l ~ -I ~ ~ ~ q)
~ .
u~
U~ ~ d' ~1 ~r o u~ ~d
o ~
~ ~ .
r~ c~ u~ I h
~ ~ ~ ~ O U~ O
,1 ,,
O ~ O ~ ~1
o o o o o o ~
o o o o o o o o o ~o
o o o o. o o o o ~
U~
c o~
-- 15 --
- . , ~ , : . : . :.
., ~
' " '. . : - ., . : ~
..
.
: . . : .
. . .- `:, ' ` ' ~ :
: ` :;
2 0 ~ 4
The slow-release tablets of the instant invention maintain
---a stable di-ssolution rate in an dissolution test for a
prolonged period of time without being influenced by pH
conditions. Further, the tablets of the instant invention
maintain a stable blood concentration of active agents, in
humans (p~o.) for example, over an extended period of time and
without sacrificing bioavailability.
While the invention has been described in detail and with
reference to specific examples thereof, it will be apparent to
one skilled in the art that various changes and modifications
can be made therein without departing from the spirit and scope
thereof.
- 16 -
.
.
: ~ : .
